CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

MLA

Sarah M. Larson, et al. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Sept. 2022. EBSCOhost, https://doi.org/10.1101/2022.09.13.22279873.

APA

Sarah M. Larson, Christopher M. Walthers, Brenda Ji, Sanaz N. Ghafouri, Jacob Naparstek, Jacqueline Trent, Jia Ming Chen, Mobina Roshandell, Caitlin Harris, Mobina Khericha Gandhi, Thomas Schweppe, Beata Berent-Maoz, Stanley B. Gosliner, Amr Almaktari, Martin Allen-Auerbach, Jonathan Said, Karla Nawaly, Monica Mead, Sven De Vos, … Yvonne Y. Chen. (2022). CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. https://doi.org/10.1101/2022.09.13.22279873

Chicago

Sarah M. Larson, Christopher M. Walthers, Brenda Ji, Sanaz N. Ghafouri, Jacob Naparstek, Jacqueline Trent, Jia Ming Chen, et al. 2022. “CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma,” September. doi:10.1101/2022.09.13.22279873.